Suchergebnisse - Mark Guinter

The BEV1L study: Do real‐world outcomes associated with the addition of bevacizumab to first‐line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?... Autoría: Linda R. Duska, Jonathan Lim, Tirza Areli Calderón Boyle, Mark Guinter, Siobhan Halloran, John Hartman, Jeanne M. Schilder, Jean A. Hurteau, Amanda K. Golembesky